Nothing Special   »   [go: up one dir, main page]

EP1855719A4 - Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus - Google Patents

Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus

Info

Publication number
EP1855719A4
EP1855719A4 EP06720569A EP06720569A EP1855719A4 EP 1855719 A4 EP1855719 A4 EP 1855719A4 EP 06720569 A EP06720569 A EP 06720569A EP 06720569 A EP06720569 A EP 06720569A EP 1855719 A4 EP1855719 A4 EP 1855719A4
Authority
EP
European Patent Office
Prior art keywords
sars
cov
acute respiratory
respiratory syndrome
severe acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06720569A
Other languages
German (de)
French (fr)
Other versions
EP1855719A2 (en
Inventor
Shibo Jiang
Yuxian He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center Inc
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Priority to EP10151641A priority Critical patent/EP2193802B1/en
Priority to DK10151641.7T priority patent/DK2193802T3/en
Publication of EP1855719A2 publication Critical patent/EP1855719A2/en
Publication of EP1855719A4 publication Critical patent/EP1855719A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.
EP06720569A 2005-02-08 2006-02-08 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus Withdrawn EP1855719A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10151641A EP2193802B1 (en) 2005-02-08 2006-02-08 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
DK10151641.7T DK2193802T3 (en) 2005-02-08 2006-02-08 Neutralizing monoclonal antibodies against severe acute respiratory syndrome associated with coronavirus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65104605P 2005-02-08 2005-02-08
US14192505A 2005-05-31 2005-05-31
PCT/US2006/004599 WO2006086561A2 (en) 2005-02-08 2006-02-08 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus

Publications (2)

Publication Number Publication Date
EP1855719A2 EP1855719A2 (en) 2007-11-21
EP1855719A4 true EP1855719A4 (en) 2009-11-04

Family

ID=36793717

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06720569A Withdrawn EP1855719A4 (en) 2005-02-08 2006-02-08 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus

Country Status (10)

Country Link
EP (1) EP1855719A4 (en)
JP (1) JP2008529504A (en)
AT (1) ATE556717T1 (en)
AU (1) AU2006213775C1 (en)
BR (1) BRPI0606148A2 (en)
CA (1) CA2595780A1 (en)
ES (1) ES2384497T3 (en)
MX (1) MX2007009512A (en)
NZ (1) NZ560328A (en)
WO (1) WO2006086561A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61549B1 (en) * 2014-06-12 2021-04-29 Univ Do Porto Reitoria Vaccine for immunocompromised hosts
CN113292650B (en) * 2020-02-24 2022-08-12 中国科学院微生物研究所 Human monoclonal antibodies to novel coronaviruses and uses thereof
CN113292649B (en) * 2020-02-24 2022-08-12 中国科学院微生物研究所 Human monoclonal antibodies to novel coronaviruses and uses thereof
CN113391064A (en) * 2020-03-13 2021-09-14 科美诊断技术股份有限公司 Receptor reagent for detecting novel coronavirus neutralizing antibody and application thereof
CN111560074B (en) * 2020-03-20 2021-07-09 中山大学 Novel coronavirus S protein single-region subunit nano vaccine based on helicobacter pylori ferritin
CN111983226A (en) * 2020-03-25 2020-11-24 新加坡国立大学 Detection of SARSr-CoV antibodies
WO2021202893A1 (en) * 2020-04-03 2021-10-07 Nonigenex, Inc. Detecting adaptive immunity to coronavirus
JP7174961B2 (en) * 2020-05-01 2022-11-18 花王株式会社 Medicines and test kits using anti-SARS-CoV-2 antibodies
CN111995675B (en) * 2020-05-15 2021-03-23 潍坊医学院 Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof
WO2021238910A1 (en) * 2020-05-25 2021-12-02 Guo Bingshi Anti-coronavirus spike protein antibodies and uses thereof
CN112017782A (en) * 2020-06-01 2020-12-01 北京松果天目健康管理有限公司 Method for detecting susceptibility of SARS-CoV-2 and method for predicting severe risk of novel coronavirus
AU2021297998A1 (en) * 2020-06-25 2022-12-15 Gliknik Inc. ACE2-Fc fusion proteins and methods of use
JP7516652B2 (en) 2020-07-16 2024-07-16 ケアジェン カンパニー，リミテッド Peptides with neutralizing activity against severe acute respiratory syndrome coronavirus type 2
CN113945714B (en) * 2020-07-16 2023-01-31 南京蓬勃生物科技有限公司 Method for detecting neutralizing capacity of novel coronavirus neutralizing antibody drugs
CN112010984B (en) * 2020-08-04 2021-10-12 广州千扬生物医药技术有限公司 Novel coronavirus S protein polymer nano vaccine based on helicobacter pylori ferritin
EP4206224A1 (en) 2020-08-26 2023-07-05 National University Corporation Kumamoto University Human antibody or antigen-binding fragment thereof against coronavirus spike protein
CN114181301B (en) * 2020-09-14 2023-04-28 复旦大学 ADE-effect-free neutralizing antibodies against SARS-CoV-2
CN113156129B (en) * 2021-01-13 2022-04-05 广东菲鹏生物有限公司 High-sensitivity detection method and product of neutralizing antibody
US20240158477A1 (en) * 2021-01-27 2024-05-16 Bioduro (Jiangsu) Co., Ltd. Antibody against sars-cov-2
CN113150130B (en) * 2021-01-31 2022-10-18 中南大学湘雅医院 Novel coronavirus monoclonal antibody and application thereof
CN114859042B (en) * 2021-02-03 2023-11-03 广东菲鹏生物有限公司 Method and reagent for identifying antibody combined with mutant antigen
EP4089112A1 (en) * 2021-05-14 2022-11-16 Ustav organicke chemie a biochemie AV CR, v.v.i. Antibody binding to rbd of spike protein of sars-cov-2 and a method for quantifying protective antibodies against sars-cov-2
WO2023148641A1 (en) * 2022-02-02 2023-08-10 Translational Health Science And Technology Institute Monoclonal antibodies specific to receptor binding domain of sars-cov2 and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BABCOCK GREGORY J ET AL: "Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor", JOURNAL OF VIROLOGY, vol. 78, no. 9, May 2004 (2004-05-01), pages 4552 - 4560, XP002546670, ISSN: 0022-538X *
HE Y ET AL: "Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 325, no. 2, 10 December 2004 (2004-12-10), pages 445 - 452, XP004626814, ISSN: 0006-291X *
TRAGGIAI E ET AL: "An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 10, no. 8, 11 July 2004 (2004-07-11), pages 871 - 875, XP002385893, ISSN: 1078-8956 *
XIAO X ET AL: "The SARS-CoV S glycoprotein: expression and functional characterization", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 312, no. 4, 26 December 2003 (2003-12-26), pages 1159 - 1164, XP004476398, ISSN: 0006-291X *

Also Published As

Publication number Publication date
CA2595780A1 (en) 2006-08-17
AU2006213775B2 (en) 2010-11-11
AU2006213775A1 (en) 2006-08-17
JP2008529504A (en) 2008-08-07
AU2006213775C1 (en) 2011-11-03
WO2006086561A2 (en) 2006-08-17
ES2384497T3 (en) 2012-07-05
ATE556717T1 (en) 2012-05-15
NZ560328A (en) 2010-05-28
MX2007009512A (en) 2008-02-21
WO2006086561A3 (en) 2009-04-23
EP1855719A2 (en) 2007-11-21
BRPI0606148A2 (en) 2009-06-02

Similar Documents

Publication Publication Date Title
EP1855719A4 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
CY1108689T1 (en) Oligopeptides for Reducing Increased Urine Concentration in Blood
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
CR8698A (en) MONOCLONAL ANTIBODIES TO THE HEPATOCITE GROWTH FACTOR
NO20083895L (en) Anti-IGF-1R human monoclonal antibody formulation
EA200870538A1 (en) LYOPHYLIZED COMPOSITIONS ANTI-EGFR ANTIBODIES
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
EA200970469A1 (en) ANTIBODY-AGONISTS OF THE TRKB RECEPTOR AND THEIR APPLICATION
ZA200405389B (en) Binding proteins as biosensors
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
NO20092522L (en) Compositions and Methods for Treating Cancer with Cupredoxins and CPG Rich DNA
WO2005012337A3 (en) Antigenic peptides of sars coronavirus and uses thereof
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
TW200740840A (en) Diagnostic test kits
WO2008103849A3 (en) Methods and compounds for lymphoma cell detection and isolation
WO2009070507A3 (en) Anaplasma phagocytophilum (aph) antigens and antibodies specific for anaplasma
BRPI0815460A2 (en) diagnostic kit or device and method for predicting cancer in mammalian subjects
WO2010031749A9 (en) Compositions and methods for detecting tlr3
EP2193802A3 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
WO2020041360A8 (en) Dbpa antibodies and uses thereof
GB2455929A (en) A method for the identification of human immunodeficiency virus related antibodies in blood
GB0706558D0 (en) Diagnostic assay
ATE434044T1 (en) ANTIBODIES AGAINST TUMOR-SPECIFIC ANTIGEN AS A TARGET
WO2022200291A3 (en) Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070828

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20090423

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/215 20060101ALI20090619BHEP

Ipc: A61K 39/42 20060101ALI20090619BHEP

Ipc: A61K 39/395 20060101ALI20090619BHEP

Ipc: A61K 39/00 20060101AFI20090619BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091002

17Q First examination report despatched

Effective date: 20100408

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100819